Related Experiment Videos
Functional adiponectin resistance and exercise intolerance in heart failure.
An M Van Berendoncks1, Viviane M Conraads
1Department of Cardiology and Laboratory for Cellular and Molecular Cardiology, Antwerp University Hospital, Wilrijkstraat 10, Edegem 2650, Belgium. An.vanberendoncks@ua.ac.be
Current Heart Failure Reports
|March 23, 2011
Summary
Skeletal muscle myopathy contributes to chronic heart failure (CHF) phenotypes. Elevated adiponectin in CHF patients suggests functional adiponectin resistance, offering potential therapeutic targets.
Area of Science:
- Cardiovascular Disease
- Skeletal Muscle Physiology
- Metabolic Research
Background:
- Skeletal muscle myopathy is a recognized contributor to chronic heart failure (CHF) phenotypes.
- Functional abnormalities in skeletal muscle, including insulin resistance, occur early in CHF progression.
- Adipokines, particularly adiponectin, are investigated for their role in CHF-related skeletal myopathy.
Purpose of the Study:
- To explore the role of adiponectin in skeletal muscle dysfunction in chronic heart failure.
- To investigate the concept of functional adiponectin resistance in CHF patients.
- To identify potential therapeutic targets related to adiponectin signaling in CHF.
Main Methods:
- Analysis of skeletal muscle changes in chronic heart failure patients.
- Measurement of circulating adiponectin levels in CHF cohorts.
- Investigation of adiponectin signaling pathways in skeletal muscle.
Main Results:
- Circulating adiponectin levels are elevated in CHF patients, contrary to cardiovascular disease risk groups.
- Increased adiponectin levels in CHF are associated with adverse outcomes.
- A concept of functional skeletal muscle adiponectin resistance is proposed for CHF.
Conclusions:
- Adiponectin plays a critical role in skeletal muscle metabolism and CHF.
- Elevated adiponectin in CHF may indicate functional resistance rather than deficiency.
- Understanding adiponectin resistance pathways could lead to novel therapeutic strategies for CHF.
Related Concept Videos
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:30Heart Failure VII: Nursing Interventions
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...